Eli Lilly and Co. (NYSE: LLY) has secured a $625 million contract modification to supply 500,000 more doses of the company’s COVID-19 monoclonal antibody drug to the U.S. Army. Army Contracting Command obligated the full amount of the modification using fiscal 2021 Coronavirus Aid, Relief and Economic Security Act funds, …
Read More »DoD, HHS Sign $375M Procurement Deal for Eli Lilly COVID-19 Drug
Eli Lilly and Co. (NYSE: LLY) has received a potential $375M contract from the departments of Defense and Health and Human Services to initially supply 300K doses of bamlanivimab, an investigational monoclonal antibody drug for COVID-19.
Read More »